ArticleInvestigative ophthalmology & visual science2026
Hepatocyte Growth Factor Confers Trabecular Meshwork Stem Cell Resilience and Paracrine Protection of Trabecular Meshwork Cells in Glaucoma.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Author Response: Human Trabecular Meshwork and Hepatocyte Growth Factor.Investigative ophthalmology & visual science · 2026Article
- Human Trabecular Meshwork and Hepatocyte Growth Factor.Investigative ophthalmology & visual science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Purpose: We have reported that trabecular meshwork stem cells (TMSCs) are effective for trabecular meshwork (TM) regeneration. This study aims to investigate different responses of TMSCs and TM cells to TGF-β2 and protective factors in TMSCs. Methods: Human TMSCs and TM cells were exposed to TGF-β2 with or without antioxidant N-acetylcysteine, TMSC-derived secretome (TMSC-Scr), hepatocyte growth factor (HGF), or HGF receptor inhibitor (HGFI). Cell viability was assessed by the MTT assay. Intracellular reactive oxygen species (ROS) and lipid peroxidation were measured using CellROX and C11-BODIPY, respectively. Mitochondrial membrane potential was assessed using tetramethylrhodamine methyl ester (TMRM). Fibrotic markers (fibronectin, α-SMA, CTGF) were evaluated by immunofluorescent staining and Western blotting. RNA sequencing was performed to compare transcriptional profiles between TMSCs and TM cells. A cytokine array was used to compare TMSC-Scr and TM-Scr. A t-test or ANOVA followed by Tukey's multiple comparisons test was used for statistical analysis, with significance defined as P < 0.05. Results: Compared with TM cells, TMSCs exhibited greater survival, better-preserved mitochondrial function, and lower levels of ROS, lipid peroxidation, and fibrotic marker expression after TGF-β2 treatment. N-acetylcysteine partially prevented TGF-β2 effects on TM cells. RNA sequencing and cytokine analyses identified significant enrichment of HGF in TMSCs and TMSC-Scr. TMSC-Scr and HGF markedly reduced oxidative and fibrotic responses to TGF-β2 in TM cells, whereas an HGFI abolished this protective effect. Conclusions: Our findings confirm that TMSC-Scr and HGF are promising candidates for cell-free therapies in glaucoma. HGF confers intrinsic resilience in TMSCs and functions as a key, but partial, mediator of their protection of TM cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.